Researchers conducted a small study to see if a medication called tadalafil could affect blood markers related to Alzheimer's disease in people with type 2 diabetes. The study involved only 15 people who were given either tadalafil or a placebo for six weeks. The researchers then looked at several proteins in the blood that are associated with brain changes in Alzheimer's.
They found that people taking tadalafil had lower levels of two amyloid proteins and one protein called GFAP compared to those taking the placebo. However, other important markers, including one called p-tau217, did not change. The study did not report on side effects or whether people felt any different.
It is important to be very cautious about these results. This was a very small study that only measured blood markers for a short time. It does not tell us if tadalafil improves memory, slows Alzheimer's disease, or is safe for this purpose. The changes in biomarkers are a first step that needs much more research in larger groups over longer periods.
For now, this study simply suggests that tadalafil might influence some biological signals related to Alzheimer's in people with diabetes. It is far too early to consider this a treatment. More research is needed to understand what these biomarker changes mean for brain health.
